An entrepreneurial and human adventure
More than 20 years of experience and continuous growth

<p>Foundation of Provence Technologies, a <strong>research and development chemistry laboratory</strong>, resulting from the association of the 2 founding partners: Michel FERAUD and Christophe BARALOTTO. The company operates as a subcontractor for biotechnological companies and international pharmaceutical groups. The company thus builds its reputation in different fields such as pharmaceuticals, cosmetics and agrochemicals.</p>

<p>Given its solid financial structure, Provence Technologies launches several internal research programs. One of them concerns a new process for the synthesis of methylene blue, which led to <strong>the filing of a international patent in 2006.</strong> A year later, in 2007, Provepharm, a subsidiary of Provence Technologies, was founded to develop and commercialize this product.</p>

<p><strong>Obtains a Centralized Marketing Authorization</strong> paving the way for the commercialization of Proveblue<sup>®</sup> in the 30 countries of the enlarged European Union: the authorities recognize patient benefit of Proveblue<sup>®</sup>.</p>
<p>Thus, Michel FERAUD, co-inventor with Babak SAYAH of this patent, also becomes President and builds a team of professionals as well as a committee of internationally renowned experts.</p>

<p>The group acquires a company specialized in the<strong>chemical synthesis of peptides and proteins for therapeutic use.</strong> This operation opens a new development path for the company in the field of biological pharmaceutical products.</p>

<p>An important milestone is reached: Provepharm <strong>obtains FDA approval </strong>to commercialize ProvayBlue<sup>™</sup>, its Injectable Methylene Blue.</p>

<p>The company becomes <strong>Provepharm Life Solutions</strong> and launches its new brand identity. The adventure continues!</p>

<p>Provepharm Life Solutions joins forces with <strong>new strategic partners</strong>, <a href="https://www.archimed.fr/" rel="noopener" target="_blank">A</a><a href="http://www.archimed-group.eu/" rel="noopener" target="_blank">rchiMed</a> et <a href="https://www.tethysinvestments.com/" rel="noopener" target="_blank">Téthys Invest</a>.</p>

<p>Obtains a <strong>42.5 M€ syndicated loan</strong> </p>
<p> </p>
<p><strong>Inauguration of the pilot plant</strong> located at Château Gombert, Marseille, head office.</p>

<p>Provepharm Life Solutions acquires <strong>Apollo Pharmaceuticals USA</strong>, a company specialized in sterile injectable products with high added-value, to continue its growth in the United States.</p>
<p> </p>
<p><a href="https://www.provepharm.com/en/news/provepharm-life-solutions-acquires-apollo-pharmaceuticals-usa">Read more.</a></p>
<p> </p>